Nati-Castillo H, Aristizabal-Colorado D, Lopez Ordonez C, Egas Proano D, Ortiz-Prado E, Izquierdo-Condoy J
Int J Cardiol Cardiovasc Risk Prev. 2024; 22:200292.
PMID: 38872732
PMC: 11170171.
DOI: 10.1016/j.ijcrp.2024.200292.
Jaiswal V, Ang S, Deb N, Hanif M, Batra N, Kanagala S
Medicina (Kaunas). 2024; 60(4).
PMID: 38674227
PMC: 11052115.
DOI: 10.3390/medicina60040580.
Irelli A, Ceriello L, Patruno L, Tessitore A, Alesse E, Cannita K
Biomedicines. 2024; 12(1).
PMID: 38255284
PMC: 10813278.
DOI: 10.3390/biomedicines12010179.
Osawa T, Tajiri K, Ieda M, Ishizu T
Front Cardiovasc Med. 2023; 10:1244808.
PMID: 37840966
PMC: 10570743.
DOI: 10.3389/fcvm.2023.1244808.
Panday P, Hausvater A, Pleasure M, Smilowitz N, Reynolds H
Am J Cardiol. 2023; 194:27-33.
PMID: 36931164
PMC: 10984272.
DOI: 10.1016/j.amjcard.2023.02.007.
Trigger related outcomes of takotsubo syndrome in a cancer population.
Safdar A, Ahmed T, Liu V, Addoumieh A, Agha A, Giza D
Front Cardiovasc Med. 2022; 9:1019284.
PMID: 36386379
PMC: 9651211.
DOI: 10.3389/fcvm.2022.1019284.
Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report.
Fukuda Y, Kawa Y, Nonaka A, Shiotani H
Clin Case Rep. 2022; 10(9):e6279.
PMID: 36093451
PMC: 9440339.
DOI: 10.1002/ccr3.6279.
Takotsubo Syndrome: Translational Implications and Pathomechanisms.
Fan X, Yang G, Kowitz J, Akin I, Zhou X, El-Battrawy I
Int J Mol Sci. 2022; 23(4).
PMID: 35216067
PMC: 8875072.
DOI: 10.3390/ijms23041951.
Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis.
Kim J, Nishimura Y, Kewcharoen J, Yess J
J Clin Med. 2021; 10(16).
PMID: 34442027
PMC: 8397057.
DOI: 10.3390/jcm10163731.
Atypical Takotsubo Cardiomyopathy Secondary to Combination of Chemo-Immunotherapy in a Patient With Non-Small Cell Lung Cancer.
Jang Khan N, Pacioles T, Alsharedi M
Cureus. 2020; 12(7):e9429.
PMID: 32742890
PMC: 7389888.
DOI: 10.7759/cureus.9429.
Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry.
Cammann V, Sarcon A, Ding K, Seifert B, Kato K, Di Vece D
J Am Heart Assoc. 2019; 8(15):e010881.
PMID: 31311438
PMC: 6761645.
DOI: 10.1161/JAHA.118.010881.
Takotsubo syndrome: an overview of pathophysiology, diagnosis and treatment with emphasis on cancer patients.
Costa I, Figueiredo C, Fonseca S, Bittar C, de Carvalho Silva C, Rizk S
Heart Fail Rev. 2019; 24(6):833-846.
PMID: 31197563
DOI: 10.1007/s10741-019-09813-1.
Omalizumab induced Takotsubo syndrome: case report.
Aguiar-Ricardo I, Nunes-Ferreira A, Roda A, Bras-Rosario L
Eur Heart J Case Rep. 2019; 3(1):yty155.
PMID: 31020231
PMC: 6439385.
DOI: 10.1093/ehjcr/yty155.
Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostubo's cardiomyopathy.
Giza D, Moudgil R, Lopez-Mattei J, Kim P, Iliescu C
Eur Heart J Case Rep. 2019; 1(2):ytx006.
PMID: 31020065
PMC: 6177044.
DOI: 10.1093/ehjcr/ytx006.
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy.
Brunetti N, Tarantino N, Guastafierro F, De Gennaro L, Correale M, Stiermaier T
Heart Fail Rev. 2019; 24(4):481-488.
PMID: 30806878
DOI: 10.1007/s10741-019-09773-6.
International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology.
Ghadri J, Wittstein I, Prasad A, Sharkey S, Dote K, Akashi Y
Eur Heart J. 2018; 39(22):2032-2046.
PMID: 29850871
PMC: 5991216.
DOI: 10.1093/eurheartj/ehy076.
Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients.
Joy P, Guddati A, Shapira I
J Cancer Res Clin Oncol. 2018; 144(8):1539-1545.
PMID: 29761372
DOI: 10.1007/s00432-018-2661-1.
Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature.
Coen M, Rigamonti F, Roth A, Koessler T
BMC Cancer. 2017; 17(1):394.
PMID: 28578653
PMC: 5457651.
DOI: 10.1186/s12885-017-3384-4.
Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.
Cheungpasitporn W, Kopecky S, Specks U, Bharucha K, Fervenza F
J Renal Inj Prev. 2017; 6(1):18-25.
PMID: 28487867
PMC: 5414514.
DOI: 10.15171/jrip.2017.04.
Cancer as a Risk Factor for Cardiovascular Disease.
Giza D, Iliescu G, Hassan S, Marmagkiolis K, Iliescu C
Curr Oncol Rep. 2017; 19(6):39.
PMID: 28421481
DOI: 10.1007/s11912-017-0601-x.